# Outpace Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/outpace-bio

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.outpacebio.com/
- Total disclosed funding: $81M
- Latest round: Series B (Jul 17, 2024)
- Investors on record: 17

## About

Outpace Bio, Inc. is a Seattle-based biotechnology firm specializing in cell therapy solutions aimed at enhancing cancer treatments through advanced protein design technologies.Founded in 2020, Outpace Bio, Inc. focuses on developing innovative treatments for cancer through engineered cell therapies. The company has completed three funding deals, including the latest Series B round, which raised USD 56.00 mn on July 17, 2024, led by RA Capital with participation from multiple venture firms. Marc Lajoie, one of the founders, serves as CEO.Outpace Bio, Inc. specializes in innovative cell therapy solutions that leverage advanced protein design technologies to enhance the efficacy and safety of cancer treatments. Their primary offerings include the OUTSMART™, OUTLAST™, OUTSPACER™, OUTSAFE™, and CO-LOCKR™ technologies, which work collaboratively to address the critical challenges faced in solid tumor treatment. By programming engineered cells to recognize and eliminate cancer while navigating the complexities of the tumor microenvironment, these products collectively aim to improve immune response, enhance cell therapy persistence, and provide precise targeting of cancer cells. Outpace Bio's technologies cater to biopharmaceutical companies and research institutions focused on cancer therapeutics, with applications in diverse geographical markets including North America and Europe.Outpace Bio generates revenue through partnerships and collaborations with biopharmaceutical firms and academic institutions that seek to harness their advanced cell therapy technologies. The company engages in B2B transactional structures, allowing clients to access their proprietary technologies through licensing agreements or collaborative research initiatives. Financial arrangements may involve co-development agreements or milestone-based payments tied to the successful progression of therapeutic candidates through clinical trials, structured to align with partner needs.On July 17, 2024, Outpace Bio, Inc. raised USD 59.99 mn in Series B financing led by RA Capital Management, with participation from various investors. The company plans to use the funding to advance multiple cell product treatments for tumors, focusing on expanding their offerings and increasing their market penetration in North America and Europe. Specific new products are expected to be developed, although release dates have not been disclosed.

## Funding rounds

- Series B, Jul 17, 2024, $56M — Alexandria Venture Investments, ARTIS Ventures, WRF Capital, RA Capital Management, Breton Capital Ventures, Bristol-Myers Squibb Company, Playground Ventures, Abstract Ventures, Mubadala Capital, Civilization Ventures, Surveyor Capital, Sahsen Foundation, Black Opal Ventures, Qatar Investment Authority, Sheatree Capital
- Series A, Aug 4, 2021, $25M — ARTIS Ventures, WRF Capital, Playground Ventures, Gaingels, Abstract Ventures, Mubadala Capital, Civilization Ventures, Sahsen Foundation, Lyell Immunopharma, Inc.

## Investors

- ARTIS Ventures (https://capitalatlas.ai/funds/artis-ventures) — Series A, Series B
- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series A, Series B
- Playground Ventures (https://capitalatlas.ai/funds/playground-ventures) — Series A, Series B
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series A
- Abstract Ventures (https://capitalatlas.ai/funds/abstract-ventures) — Series A, Series B
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series A, Series B
- Civilization Ventures (https://capitalatlas.ai/funds/civilization-ventures) — Series A, Series B
- Sahsen Foundation — Series A, Series B
- Lyell Immunopharma, Inc. — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Breton Capital Ventures (https://capitalatlas.ai/funds/breton-capital-ventures) — Series B
- Bristol-Myers Squibb Company — Series B
- Surveyor Capital — Series B
- Black Opal Ventures (https://capitalatlas.ai/funds/black-opal-ventures) — Series B
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B
- Sheatree Capital — Series B